# Lipids, Inflammation, and CV Risk in RA

> **NCT02714881** · — · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 74 (actual)

## Conditions studied

- Rheumatoid Arthritis
- Cardiovascular Disease

## Interventions

- **DRUG:** Certolizumab

## Key facts

- **NCT ID:** NCT02714881
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-17
- **Primary completion:** 2020-12-14
- **Final completion:** 2022-12-21
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2026-01-21

## Collaborators

- National Heart, Lung, and Blood Institute (NHLBI)

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02714881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02714881, "Lipids, Inflammation, and CV Risk in RA". Retrieved via AI Analytics 2026-08-31 from https://api.ai-analytics.org/clinical/NCT02714881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*